IMiDs have been associated with some degree of renal recovery with manageable toxicity profile and should be considered especially for bortezomib-refractory patients.Treatment choices should be individualized and based on previous lines of therapy, and specific patients and disease characteristics.
Meletios A Dimopoulos, Pieter Sonneveld, Nelson Leung, Giampaolo Merlini, Heinz Ludwig, Efstathios Kastritis, Hartmut Goldschmidt, Douglas Joshua, Robert Z. Orlowski, Raymond Powles, David H. Vesole, Laurent Garderet, Hermann Einsele, Antonio Palumbo, Michèle Cavo, Paul G. Richardson, Philippe Moreau, Jesús F. San Miguel, S. Vincent Rajkumar, Brian G.M. Durie, Evangelos Terpos
Meletios A Dimopoulos, Joseph Mıkhael, Evangelos Terpos, Xavier Leleu, Philippe Moreau, Joan Bladé, Jin Seok Kim, Keith Stockerl‐Goldstein, Paul G. Richardson
Discussion(0)
No comments yet. Be the first to comment.